Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27473301 | 1.00 | MEN1 (0.38) | MEN1ALDH1A1KMT2APGRNOTUM | |
| SCHEMBL31326515 | 1.00 | MEN1 (0.38) | MEN1ALDH1A1KMT2APGRNOTUM | |
| SCHEMBL13573738 | 1.00 | MEN1 (0.38) | MEN1ALDH1A1KMT2APGRNOTUM | |
| SCHEMBL24819998 | 1.00 | MEN1 (0.38) | MEN1ALDH1A1KMT2APGRNOTUM | |
| SCHEMBL13080848 | 1.00 | MEN1 (0.38) | MEN1ALDH1A1KMT2APGRNOTUM | |
| SCHEMBL24822696 | 1.00 | MEN1 (0.38) | MEN1ALDH1A1KMT2APGRNOTUM | |
| SCHEMBL413656 | 0.84 | ALDH1A1 (0.43) | MEN1ALDH1A1KMT2ANOTUMNOS3 | |
| SCHEMBL30298332 | 0.84 | ALDH1A1 (0.43) | MEN1ALDH1A1KMT2ANOTUMNOS3 | |
| Bromide SCHEMBL28348255 | 0.81 | ALDH1A1 (0.42) | MEN1ALDH1A1KMT2ANOTUMNOS3 | |
| SCHEMBL15000999 | 0.81 | TAS1R3 (0.38) | MEN1KMT2ANOTUMNOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-3661943-B1 | COMPOSITION CONTAINING FURFURYL SILICATES AND FURFURYL ALCOHOL | HUETTENES ALBERTUS CHEMISCHE WERKE GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| EP-3661943-A1 | COMPOSITION CONTAINING FURFURYL SILICATES AND FURFURYL ALCOHOL | HÜTTENES-ALBERTUS Chemische Werke Gesellschaft mit beschränkter Haftung (DE) | 2020-06-10 | — | — | EP | disclosed |
| US-20110178143-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178143-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178143-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2188261-A1 | THERAPEUTIC COMPOUNDS | Allergan, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| WO-2009023757-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009023757-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| EP-1250342-B1 | BRIDGED METALLOCENE COMPOUNDS AS OLEFIN-POLYMERIZATION CATALYSTS | POLIMERI EUROPA SPA (IT) | 2006-06-28 | — | — | EP | disclosed |
| US-6984703-B1 | Bridged metallocene compounds as olefin-polymerization catalysts | POLIMERI EUROPA S.P.A. (IT) | 2006-01-10 | — | — | US | disclosed |
| EP-1250342-A1 | BRIDGED METALLOCENE COMPOUNDS AS OLEFIN-POLYMERIZATION CATALYSTS | Polimeri Europa S.p.A. (IT) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001040238-A1 | BRIDGED METALLOCENE COMPOUNDS AS OLEFIN-POLYMERIZATION CATALYSTS | POLIMERI EUROPA S.P.A. (IT) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178143-A1 | THERAPEUTIC COMPOUNDS | GOT2, GOT1, ANXA5 | MEN1 3253/4885ALDH1A1 762/4885KMT2A 4369/4885 |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2A, ADRA2C | MEN1 3674/4885ALDH1A1 434/4885KMT2A 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.